This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q26.4 (Anomalous pulmonary venous connection, unspecified) | Special Copayment Reduction: V150 |
| B. Synonyms | Anomalous pulmonary venous connection, unspecified |
| C. Adult onset | Likelihood of first presentation in adulthood: moderate — the timing of presentation varies according to the type of anomaly included under the unspecified classification and the degree of shunting. Partial anomalies with mild shunting are commonly found incidentally in adulthood, and those with moderate or greater shunting may first be diagnosed in adulthood with reduced exercise capacity, dyspnea, atrial arrhythmias, etc. |
| 1. History | History of the development of classification systems for anomalous pulmonary venous connection; conceptual position of Q26.4; its role as an umbrella code in the ICD-10 coding system. |
| 2. Causes | Abnormal development of the pulmonary vein–left atrium connection in fetal life; a broad developmental background encompassing both partial and total anomalous pulmonary venous connection. |
| 3. Genetics | Mostly sporadic; possible involvement of cardiac development genes such as NKX2-5, GATA4, and TBX5; association with syndromic anomalies. |
| 4. General epidemiology | Q26.4 is used as an umbrella code for anomalous pulmonary venous connection; actual frequency is included in Q26.3 (partial) and Q26.2 (total); used when the diagnosis is incomplete. |
| 5. Pathophysiology | Abnormal pulmonary venous connection → left-to-right shunt or pulmonary venous obstruction → mechanism of right heart overload or pulmonary venous hypertension. |
| 6. Symptoms | Diverse clinical spectrum according to anomaly type and shunt volume; from asymptomatic to dyspnea, cyanosis, and heart failure. |
| 7. Signs | Signs of right heart overload or pulmonary venous hypertension; auscultation, ECG, chest X-ray, and echocardiographic findings. |
| 8. Screening | Screening by echocardiography; anatomical confirmation by CT and MRI; hemodynamic assessment by cardiac catheterization. |
| 9. Diagnosis | Echocardiography, CT angiography, cardiac MRI, cardiac catheterization; accurate establishment of the anatomical classification is key to treatment planning. |
| 10. Treatment | Surgical correction (choice of technique by anomaly type); supportive medical therapy; pulmonary vasodilators (when hypertension is present). |
| 11. Prognosis | Varies according to anomaly type and shunt volume; good with early correction; correction before progression of pulmonary arterial hypertension is key. |
| 12. Prevention | Primary prevention is difficult; early establishment of anatomical diagnosis and timely surgical correction; regular cardiac follow-up after correction. |
| 13. References | Seale AN et al., Heart 2010; Karamlou T et al., J Thorac Cardiovasc Surg 2006, and 8 other references |
ICD-10 code Q26.4 (anomalous pulmonary venous connection, unspecified) is a collective term for congenital heart malformations in which the pulmonary veins do not connect normally to the left atrium; it is an umbrella code used when the anatomical type has not been fully classified, or at the clinical documentation stage before the partial (Q26.3) or total (Q26.2) classification is applied. The history of clinical recognition of anomalous pulmonary venous connection began with the pathoanatomical descriptions of European anatomists in the 17th century. In 1733, Winslow first accurately described an anomaly in which the right pulmonary veins drain into the right atrium, and various forms of connection were subsequently reported in the 19th century.
With the introduction of cardiac catheterization in the early 20th century, the hemodynamic significance of pulmonary venous anomalies was revealed, and in 1952 Lewis and Taufic reported the first surgical correction of total anomalous pulmonary venous connection. Subsequently, with advances in cardiac surgical techniques, various anatomical classification systems for anomalous pulmonary venous connection were proposed. Representatively, the classification of Darling et al. (1957) divided total anomalous pulmonary venous connection into cardiac, supracardiac, infracardiac, and mixed types, and this system is still widely used today.
In the ICD (International Classification of Diseases) system, anomalous pulmonary venous connection was classified in ICD-9 as 747.41 (partial) and 747.41 (total), and in ICD-10 it was subdivided into Q26.2 (total anomalous pulmonary venous connection), Q26.3 (partial anomalous pulmonary venous connection), and Q26.4 (unspecified). Q26.4 functions as an umbrella code used when the anatomical details of the pulmonary venous anomaly are not specified in the clinical record, or before type classification at the initial diagnostic stage. In actual clinical practice, once an accurate anatomical diagnosis is made, it should be reclassified as Q26.2 or Q26.3, but Q26.4 is sometimes used in the process of medical records or administrative coding.
With advances in modern imaging (CT angiography, cardiac MRI), anatomical confirmation of anomalous pulmonary venous connection has become far more accurate than in the past, and the frequency of Q26.4 use is decreasing. Nevertheless, Q26.4 is still used in clinical practice in emergencies, during initial evaluation in the neonatal period, or in healthcare settings with limited diagnostic information. The clinical spectrum of patients included under this code is broad, ranging from simple partial anomalies to complex total anomalies, so clinicians encountering a Q26.4 diagnosis must make efforts to achieve further anatomical clarification.
In Korea as well, analyses of health insurance claims data show Q26.4 as a claim code for some patients with anomalous pulmonary venous connection, suggesting the need for continued education and standardization to improve diagnostic precision. Accurate coding of congenital heart malformations registered under rare disease Special Copayment Reduction V150 is important for patient support and epidemiological understanding.
The causes of anomalies falling under Q26.4 (anomalous pulmonary venous connection, unspecified) essentially share the same developmental background as partial (Q26.3) and total (Q26.2) anomalous pulmonary venous connection. The pulmonary veins form between weeks 4 and 8 of embryonic development when the primitive common pulmonary vein buds from the posterior wall of the developing left atrium and connects with the pulmonary vascular plexus. Once this connection is complete, the connections with the splanchnic venous plexus and systemic venous system, to which the pulmonary vascular plexus was originally connected, must regress.
APVC (anomalous pulmonary venous connection) occurs when this regression process proceeds inappropriately. That is, if the primitive common pulmonary vein fails to connect with the left atrium and disappears, or if the primitive common pulmonary vein disappears before the left atrium–pulmonary vein connection is established, the pulmonary vascular plexus drains blood through pre-existing systemic venous connections. The location of this abnormal connection (superior vena cava, inferior vena cava, right atrium, coronary sinus, innominate vein, portal system, etc.) and its extent (all vs. some pulmonary veins) determine the various anatomical types, such as total, partial, and mixed.
Because the Q26.4 code is used when the detailed anatomical type of the anomaly is unclear, in terms of causes as well, the developmental mechanisms of anomalous pulmonary venous connection in general apply rather than a specific mechanism. Most cases occur sporadically, and it may appear with specific gene abnormalities, chromosomal abnormalities (Turner syndrome, 22q11.2 deletion, etc.), or as part of complex congenital heart malformations. Maternal diabetes, rubella infection, and exposure to teratogenic drugs such as valproic acid and isotretinoin during pregnancy are known to increase the general risk of congenital heart disease, but environmental risk factors specific to APVC have not been established.
When APVC accompanies complex congenital heart malformations (asplenia or polysplenia syndrome, heterotaxy, atrioventricular septal defect, etc.), global abnormalities of overall cardiac development act in combination to produce the pulmonary venous anomaly. In such cases, it is clinically more accurate to describe it as a detailed component of the complex malformation rather than as Q26.4. In heterotaxy, the form and severity of pulmonary venous anomalies are especially variable, and more severe total anomalous pulmonary venous connection is more frequent in right isomerism (asplenia) than in left isomerism.
The genetic basis of anomalous pulmonary venous connection, including anomalous pulmonary venous connection, unspecified (Q26.4), has not yet been fully elucidated. Most cases occur sporadically and do not follow a Mendelian inheritance pattern due to a single-gene abnormality. However, variants in several transcription factor genes that play key roles in cardiac development may have a potential association with anomalous pulmonary venous connection.
NKX2-5 (NK2 homeobox 5) is a transcription factor essential in the early stages of heart formation, and heterozygous loss-of-function variants are associated with various congenital heart malformations, including atrial septal defect, ventricular septal defect, and anomalous pulmonary venous connection. GATA4 is a transcription factor involved in heart formation and left atrial development, and associations with some atrial septal defects and pulmonary venous anomalies have been reported. TBX5 (T-box transcription factor 5) is involved in both upper limb and cardiac development and, as the causative gene of Holt-Oram syndrome (upper limb anomalies + atrial septal defect), is accompanied by pulmonary venous anomalies in some cases.
Regarding associations with chromosomal abnormalities, in Turner syndrome (45,X), anomalous pulmonary venous connection is rarely present in addition to coarctation of the aorta and bicuspid aortic valve. In 22q11.2 deletion syndrome (DiGeorge/Velocardiofacial syndrome), pulmonary venous anomalies may be present in addition to conotruncal defects and aortic arch anomalies. In heterotaxy, variants in genes related to laterality determination, such as CFC1, NODAL, and ZIC3, are associated with complex cardiac malformations including pulmonary venous anomalies.
In large congenital heart disease cohort studies using next-generation sequencing (NGS) (e.g., the Pediatric Cardiac Genomics Consortium, PCGC), rare de novo variants and copy number variants (CNVs) were found at high frequency in patients with various cardiac malformations, including pulmonary venous anomalies. In particular, variants in genes such as WHD2, MMP21, PKD1L1, ACVR2B, and FOXH1 have been reported to be associated with heterotaxy-related complex cardiac malformations. However, how frequently these gene variants are found in non-complex anomalous pulmonary venous connection classified as Q26.4 has not yet been sufficiently studied. Routine genetic testing is not currently recommended in clinical practice for patients with Q26.4, but genetic counseling is appropriate when complex malformations are present or there is a family history.
ICD-10 Q26.4 (anomalous pulmonary venous connection, unspecified) is a code covering cases in which the detailed anatomical type of the pulmonary venous anomaly is not specified; rather than being an independent epidemiological entity in itself, it partly encompasses the broad spectrum of anomalous pulmonary venous connection, including partial anomalous pulmonary venous connection (Q26.3) and total anomalous pulmonary venous connection (Q26.2).
Looking at the prevalence of anomalous pulmonary venous connection overall, total anomalous pulmonary venous connection is reported to account for about 1–3% of all congenital heart disease, at about 0.6–1.2 per 10,000 births. Partial anomalous pulmonary venous connection accounts for about 0.4–0.7% of all congenital heart disease. The frequency with which the Q26.4 code is used in actual clinical practice depends on the completeness of diagnosis, and as anatomical confirmation becomes more accurate with advances in imaging technology, the frequency of Q26.4 use is decreasing.
In administrative epidemiological studies using health insurance claims databases, Q26.4 appears in a relatively small proportion of pediatric and adolescent congenital heart disease codes, reflecting increased diagnostic precision in clinical practice. However, owing to emergencies, initial testing in the neonatal period, or limitations of medical record coding, Q26.4 remains the final code in some patients. Analyses of the detailed code distribution of patients with anomalous pulmonary venous connection among congenital heart malformations registered under Korea's rare disease Special Copayment Reduction V150 have been limited in Korea.
Sex and ethnic distributions have not been studied for Q26.4 itself and vary according to the type of anomaly included. Total anomalous pulmonary venous connection is reported to be equal between the sexes or slightly more common in males, Scimitar syndrome more common in females, and partial anomalous pulmonary venous connection without sex difference. In heterotaxy-related pulmonary venous anomalies, there are reports that right isomerism is slightly more common in males and left isomerism in females. Ethnic differences, as with congenital heart disease in general, are not large, but reported frequencies vary with access to diagnosis and the level of medical care.
The pathophysiology of anomalous pulmonary venous connection corresponding to Q26.4 varies according to the exact anatomical type of the anomaly, but the core principle lies in the abnormal blood circulation that occurs when oxygenated blood flows through abnormally connected pulmonary veins into the systemic venous system or right atrium instead of the left atrium.
Shunt formation: when the affected pulmonary veins drain into the systemic venous system (superior vena cava, inferior vena cava, right atrium, coronary sinus, innominate vein, or hepatic vein/portal system), a left-to-right shunt forms in which oxygenated blood recirculates to the right heart. The shunt volume (Qp/Qs) is determined by the number of affected pulmonary veins and the size of the affected lung segments, the presence and size of an accompanying atrial septal defect, and the level of pulmonary vascular resistance. As the shunt increases, the volume load on the right atrium and right ventricle increases, and pulmonary blood flow increases.
Pulmonary venous obstruction/stenosis: in some types (especially infracardiac total anomalous pulmonary venous connection in which the subdiaphragmatic connection is narrow or obstructed), drainage of pulmonary venous blood is impaired and pulmonary venous hypertension develops. In this case, pulmonary venous congestion and hypertension rather than shunting are the main pathophysiology, resulting in an emergency that presents in the neonatal period with severe pulmonary arterial hypertension, hypoxemia, and cyanosis.
Long-term course: a persistent left-to-right shunt causes structural remodeling that leads from increased right ventricular volume load → right ventricular dilation and eccentric hypertrophy → right ventricular dysfunction. Changes in pulmonary vascular structure due to pulmonary vascular overload (medial thickening → intimal proliferation → fibrosis) gradually increase pulmonary vascular resistance and eventually progress to pulmonary arterial hypertension. Changes in flow and pressure at the atrial level become the substrate for atrial remodeling and atrial arrhythmias (atrial fibrillation, atrial flutter). Atrial arrhythmias are a particularly important clinical complication in uncorrected adult patients and also increase the risk of stroke.
The clinical symptoms of anomalous pulmonary venous connection classified as Q26.4 vary extremely according to the anatomical type of the anomaly, the number of affected pulmonary veins, shunt volume, associated malformations, and patient age. They encompass a broad spectrum, from asymptomatic incidental findings to life-threatening cardiopulmonary failure in the neonatal period.
Symptoms in the neonatal and infant period: when the shunt is very large or accompanied by pulmonary venous obstruction (especially some cases corresponding to obstructed total anomalous pulmonary venous connection), an emergency occurs immediately after birth or within hours, with severe cyanosis, dyspnea, pulmonary edema, hypoxemia, and metabolic acidosis. Even in the non-obstructed type, rapid breathing, feeding difficulty, sweating, and poor weight gain due to increased pulmonary blood flow may appear in the neonatal period.
Symptoms in childhood: when the shunt volume is moderate, recurrent respiratory infections, reduced exercise capacity, and failure to thrive are the main symptoms. Symptoms of heart failure (tachycardia, hepatomegaly, peripheral edema) may appear.
Symptoms in adulthood: when the shunt is mild, patients may remain asymptomatic for decades and be diagnosed for the first time in adulthood with reduced exercise capacity, dyspnea, palpitations, or the onset of atrial fibrillation or atrial flutter. As pulmonary arterial hypertension progresses, dyspnea at rest, presyncope, and symptoms of right heart failure (lower-extremity edema, ascites, fatigue) appear. With progression to Eisenmenger physiology, cyanosis and exertional hypoxemia develop.
Specific symptoms may appear depending on the type of pulmonary venous anomaly. In abnormal connection to the innominate vein, when intrathoracic vascular dilation appears on chest X-ray as a 'snowman' or 'figure-of-8' silhouette, symptoms due to accompanying compression by intrathoracic vessels may be added. In infracardiac total anomalous pulmonary venous connection (connection to the portal vein or hepatic veins), pulmonary venous obstruction is common, and acute pulmonary edema in the neonatal period is especially severe.
Physical signs differ greatly according to the type of anomaly, shunt volume, presence or absence of pulmonary venous obstruction, and associated malformations. When the shunt is mild, the physical examination may show normal findings, while in severe anomalies various signs appear in combination.
Cyanosis: central cyanosis is observed with pulmonary venous obstruction or Eisenmenger physiology. In non-obstructive shunts, cyanosis is absent or mild. Cyanosis may also appear when there is a right-to-left shunt through an accompanying atrial septal defect.
Auscultation findings: when the shunt is significant, fixed splitting of the second heart sound and a systolic ejection murmur in the pulmonic area are heard. With severe pulmonary arterial hypertension, an accentuated pulmonic component of the second heart sound (P2) is observed. A tricuspid regurgitation murmur may be present.
Respiratory signs: tachypnea, use of accessory respiratory muscles, and chest retractions are observed with acute pulmonary edema or markedly increased pulmonary blood flow. Crackles may be heard on lung auscultation. In patients with chronically increased pulmonary blood flow, there are cases in which only increased lung field opacity is observed on imaging without particular respiratory symptoms.
Electrocardiogram: right axis deviation, right ventricular hypertrophy (right bundle branch block or rSR' pattern), and right atrial enlargement (peaked P wave) are observed. In the totally obstructed type, right ventricular dominance is prominent in the neonatal period. Atrial fibrillation or atrial flutter may be recorded.
Chest X-ray: increased pulmonary vascular markings, right atrial and right ventricular enlargement, and a prominent pulmonary artery. In supracardiac total anomalous pulmonary venous connection, a 'snowman' or 'figure-of-8' cardiac silhouette due to a dilated innominate vein and superior vena cava is characteristic. In the infracardiac type, findings of pulmonary edema are prominent.
Population screening for Q26.4 (anomalous pulmonary venous connection, unspecified) is not performed. However, in the following clinical situations, a pulmonary venous anomaly should be suspected and active testing performed.
Neonatal screening: when decreased oxygen saturation is detected on newborn screening using pulse oximetry (CCHD screening), a congenital heart malformation is suspected and echocardiography is performed. Total anomalous pulmonary venous connection of the obstructed type presents with cyanosis and pulmonary edema and can be detected by this screening. Types without obstruction may maintain relatively preserved initial oxygen saturation and may be missed by screening, so echocardiography is actively performed when clinically suspected.
Situations of clinical suspicion: ① when unexplained right ventricular dilation is observed on echocardiography, ② unexplained cyanosis or dyspnea in newborns and infants, ③ recurrent pneumonia or failure to thrive in children, ④ unexplained atrial fibrillation or reduced exercise capacity in adults, ⑤ when a 'snowman' silhouette or increased pulmonary vascular markings are observed on chest X-ray.
Choice of tests: transthoracic echocardiography is the first-line screening test, evaluating the sites of pulmonary venous entry and the direction of flow. If a pulmonary venous anomaly is suspected on echocardiography, anatomical confirmation proceeds with CT angiography or cardiac MRI. In neonatal emergencies, once an abnormal pulmonary venous connection is confirmed on echocardiography, immediate surgical or medical management is undertaken, and further imaging is performed after the condition stabilizes. Cardiac catheterization is used to measure pulmonary vascular resistance, to identify the shunt site through stepwise oxygen saturation measurement, and for preoperative hemodynamic assessment.
In the diagnostic process for patients classified as Q26.4, the most important goal is to accurately identify the anatomical type of the anomaly and reclassify it as Q26.2 or Q26.3. Various diagnostic imaging techniques are used in this process.
Echocardiography: transthoracic echocardiography is the noninvasive first-line tool, used to evaluate right atrial and right ventricular size, interventricular septal motion, pulmonary artery pressure, tricuspid regurgitation, and pulmonary venous inflow by color Doppler. Transesophageal echocardiography is superior to the transthoracic approach for directly visualizing the sites of pulmonary venous connection. In newborns, confirming that all pulmonary veins drain into the left atrium is essential, and if this cannot be confirmed, additional imaging is needed. Doppler echocardiography measures the direction and velocity of pulmonary venous flow and searches for abnormal entry sites.
CT angiography: the best anatomical imaging method for precisely identifying the course of the pulmonary veins, sites of abnormal connection, affected lung segments, and the systemic arterial supply vessels in Scimitar syndrome. It is essential for surgical planning, and in complex malformations three-dimensional reconstructed images aid anatomical understanding. Disadvantages are radiation exposure and contrast agents.
Cardiac MRI: has the advantage of being usable without radiation exposure for quantitative measurement of shunt volume (Qp/Qs), assessment of right ventricular volume and function, and repeated follow-up. Contrast-enhanced MR angiography (CE-MRA) confirms pulmonary venous anatomy. It is especially useful for postoperative follow-up.
Cardiac catheterization: stepwise measurement of oxygen saturation in each cardiac chamber and vessel directly measures the shunt site and Qp/Qs, and pulmonary vascular resistance is measured. Vasoreactivity testing (inhaled oxygen, nitric oxide) assesses operability. Currently, with advances in noninvasive imaging, cardiac catheterization solely for diagnostic purposes has decreased.
Treatment of Q26.4 consists of surgery or medical therapy appropriate to the type once the anatomical type of the anomaly has been accurately identified. Therefore, in patients diagnosed with the Q26.4 code, anatomical clarification must precede the start of treatment.
Surgical indications and timing: obstructed total anomalous pulmonary venous connection requires emergency surgery in the neonatal period. For non-obstructed total anomalous pulmonary venous connection, early elective surgery after diagnosis (usually within infancy) is recommended. In partial anomalous pulmonary venous connection, surgical correction is performed when Qp/Qs ≥ 1.5 or there is right ventricular dilation. In heterotaxy-related complex malformations, a staged surgical strategy is needed.
Surgical methods: the surgical method is selected according to the anatomical type of the anomaly. In total anomalous pulmonary venous connection, the key is common pulmonary vein-to-left atrium anastomosis, which anastomoses the common pulmonary vein to the left atrium, and the approach differs according to the type of connection site. In the cardiac type (connection to the coronary sinus or right atrium), intra-atrial patch repair is performed. In partial anomalous pulmonary venous connection, the Warden procedure, an intra-atrial tunnel, or direct reimplantation is used.
Drug therapy: diuretics, oxygen, and mechanical ventilatory support may be needed to stabilize the condition before surgery. When pulmonary arterial hypertension is present, pulmonary vasodilators such as inhaled nitric oxide (NO), prostacyclin derivatives, endothelin receptor antagonists, and PDE-5 inhibitors are used. When atrial fibrillation develops, anticoagulation and rhythm or rate control are needed.
The prognosis varies greatly according to the anatomical type of the anomaly, shunt volume, pulmonary vascular resistance, associated malformations, and timing of surgery. When few pulmonary veins are affected, the shunt is mild, and there are no associated malformations, the long-term prognosis after surgical correction is excellent.
Total anomalous pulmonary venous connection: with early surgical correction (in infancy) of the non-obstructed type, surgical mortality has decreased to 3–5% or less at advanced cardiac centers, and 10-year survival is 85–90% or higher. In the obstructed type, surgical mortality is higher at 5–15% due to the severe preoperative condition, and there is a long-term risk of recurrent pulmonary vein stenosis. In heterotaxy-related complex malformations, the prognosis is markedly poor.
Partial anomalous pulmonary venous connection: excellent long-term prognosis with early correction. The main postoperative complications are supraventricular arrhythmias and pulmonary vein or superior vena cava stenosis. When uncorrected until adulthood, there is a risk of progression of pulmonary arterial hypertension, and in some cases pulmonary artery pressure does not fully normalize even after corrective surgery.
Long-term follow-up: regular follow-up (echocardiography, ECG, cardiac MRI, Holter monitor) is needed after surgical correction. Pulmonary vein stenosis, arrhythmias, residual shunts, and pulmonary arterial hypertension are continuously monitored. Ongoing care at an adult congenital heart disease (ACHD) specialty clinic is recommended.
Primary prevention of anomalous pulmonary venous connection, including Q26.4, is difficult because most cases occur sporadically. General strategies to minimize the risk of fetal malformations during pregnancy (folic acid intake, rubella vaccination, avoidance of teratogenic drugs, diabetes control) may lower the overall risk of congenital heart disease, but a preventive effect specific to APVC has not been established.
Prenatal diagnosis: an abnormality of pulmonary venous entry may be suspected on fetal echocardiography (detailed ultrasound at 18–22 weeks of gestation), but fetal echocardiography often cannot fully evaluate pulmonary venous anatomy. The prenatal detection rate of total anomalous pulmonary venous connection is low, at about 20–40%, and even lower in the non-obstructed type. When a prenatal diagnosis is made, immediate surgical preparation after delivery and selection of an appropriate delivery facility (an institution capable of pediatric cardiac surgery) become possible, which can improve outcomes.
Early diagnosis and correction: newborn pulse oximetry screening, immediate echocardiography when clinically suspected, and rapid anatomical evaluation and surgical planning once a pulmonary venous anomaly is confirmed constitute the best secondary prevention strategy. In patients diagnosed with Q26.4, anatomical clarification is actively pursued without delay so as not to miss the appropriate timing of surgery.
Postoperative management: regular follow-up testing for early detection of pulmonary vein stenosis, arrhythmias, and pulmonary arterial hypertension is the core of tertiary prevention. Registration with and ongoing follow-up at an ACHD specialty clinic are recommended.